Fitchett D - Search Results

1

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. Inzucchi SE, et al. Among authors: fitchett d. Diab Vasc Dis Res. 2015 Mar;12(2):90-100. doi: 10.1177/1479164114559852. Epub 2015 Jan 14. Diab Vasc Dis Res. 2015. PMID: 25589482 Free PMC article. Review.

2

Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.

Fitchett DH, Udell JA, Inzucchi SE. Fitchett DH, et al. Eur J Heart Fail. 2017 Jan;19(1):43-53. doi: 10.1002/ejhf.633. Epub 2016 Sep 21. Eur J Heart Fail. 2017. PMID: 27653447 Free article. Review.

3

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.

Inzucchi SE, Khunti K, Fitchett DH, Wanner C, Mattheus M, George JT, Ofstad AP, Zinman B. Inzucchi SE, et al. J Clin Endocrinol Metab. 2020 Sep 1;105(9):3025-35. doi: 10.1210/clinem/dgaa321. J Clin Endocrinol Metab. 2020. PMID: 32485734 Free PMC article. Clinical Trial.

4

Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.

Anker SD, Sander LE, Fitchett DH, Zinman B, Pernille Ofstad A, Wanner C, Vedin O, Lauer S, Verma S, Yaggi HK, Inzucchi SE. Anker SD, et al. Among authors: fitchett dh. Diabetes Res Clin Pract. 2022 Apr;186:109837. doi: 10.1016/j.diabres.2022.109837. Epub 2022 Mar 18. Diabetes Res Clin Pract. 2022. PMID: 35314257 Free article.

5

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.

Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. Inzucchi SE, et al. Among authors: fitchett d. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4. Diabetes Care. 2018. PMID: 29203583 Clinical Trial.

6

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.

Zinman B, Inzucchi SE, Wanner C, Hehnke U, George JT, Johansen OE, Fitchett D; EMPA-REG OUTCOME® investigators. Zinman B, et al. Among authors: fitchett d. Diabetologia. 2018 Jul;61(7):1522-1527. doi: 10.1007/s00125-018-4630-2. Epub 2018 Apr 30. Diabetologia. 2018. PMID: 29713728 Clinical Trial.

7

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B. Fitchett D, et al. Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778. Circulation. 2019. PMID: 30586757 Free PMC article. Clinical Trial.

8

Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.

Verma S, Ji Q, Bhatt DL, Mazer CD, Al-Omran M, Inzucchi SE, Wanner C, Ofstad AP, Zwiener I, George JT, Zinman B, Fitchett D. Verma S, et al. Among authors: fitchett d. Diabetes Obes Metab. 2020 Jul;22(7):1207-1214. doi: 10.1111/dom.13991. Epub 2020 Mar 28. Diabetes Obes Metab. 2020. PMID: 32030863 Free PMC article. Clinical Trial.

9

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.

Verma S, Sharma A, Zinman B, Ofstad AP, Fitchett D, Brueckmann M, Wanner C, Zwiener I, George JT, Inzucchi SE, Butler J, Mazer CD. Verma S, et al. Among authors: fitchett d. Diabetes Obes Metab. 2020 Jul;22(7):1141-1150. doi: 10.1111/dom.14015. Epub 2020 Mar 29. Diabetes Obes Metab. 2020. PMID: 32227432 Free PMC article. Clinical Trial.

10

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.

Vaduganathan M, Inzucchi SE, Sattar N, Fitchett DH, Ofstad AP, Brueckmann M, George JT, Verma S, Mattheus M, Wanner C, Zinman B, Butler J. Vaduganathan M, et al. Among authors: fitchett dh. Diabetes Obes Metab. 2021 Dec;23(12):2775-2784. doi: 10.1111/dom.14535. Epub 2021 Oct 7. Diabetes Obes Metab. 2021. PMID: 34463409 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

232 results

Search Page